AgrawalALynskeyMT (2009) Candidate genes for cannabis use disorders: findings, challenges and directions. Addiction104: 518–532.
2.
BenyaminaAKebirOBlechaL. (2011) CNR1 gene polymorphisms in addictive disorders: a systematic review and a meta-analysis. Addict Biol16: 1–6.
3.
Bermudez-SilvaFJCardinalPCotaD (2012) The role of the endocannabinoid system in the neuroendocrine regulation of energy balance. J Psychopharmacol26: 114–124.
4.
BitencourtRMPamplonaFATakahashiRN (2008) Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats. Eur Neuropsychopharmacol18: 849–859.
5.
ButlerRKFordGKHoganM. (2012) Fear-induced suppression of nociceptive behaviour and activation of Akt signalling in the rat periaqueductal grey: role of fatty acid amide hydrolase. J Psychopharmacol. 26: 83–91.
6.
CasadioPFernandesCMurrayRM. (2011) Cannabis use in young people: the risk for schizophrenia. Neurosci Biobehav Rev35: 1779–1787.
7.
ChhatwalJPDavisMMaguschakKA. (2005) Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology30: 516–524.
8.
ClapperJRMoreno-SanzGRussoR. (2010) Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosci13: 1265–1270.
9.
CotaD (2008) Role of the endocannabinoid system in energy balance regulation and obesity. Front Horm Res36: 135–145.
10.
CotaDSandovalDAOlivieriMProdiED’alessioDAWoodsSC. (2009) Food intake-independent effects of Cb1 antagonism on glucose and lipid metabolism. Obesity (Silver Spring)17: 1641–1645.
11.
Di MarzoVDespresJP (2009) CB1 antagonists for obesity–what lessons have we learned from rimonabant?Nat Rev Endocrinol5: 633–638.
12.
FinnDP (2010) Endocannabinoid-mediated modulation of stress responses: physiological and pathophysiological significance. Immunobiology215: 629–646.
13.
GaoniYMechoulamR (1964) Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc86: 1646–1647.
14.
GomesFVReisDGAlvesFH. (2012) Cannabidiol injected into the bed nucleus of the stria terminalis reduces the expression of contextual fear conditioning via 5-HT1A receptors. J Psychopharmacol26: 104–113.
15.
HallWDegenhardtL (2007) Prevalence and correlates of cannabis use in developed and developing countries. Curr Opin Psychiatry20: 393–397.
16.
HallWDegenhardtL (2009) Adverse health effects of non-medical cannabis use. Lancet374: 1383–1391.
17.
HaugheyHMMarshallESchachtJP. (2008) Marijuana withdrawal and craving: influence of the cannabinoid receptor 1 (CNR1) and fatty acid amide hydrolase (FAAH) genes. Addiction103: 1678–1686.
18.
HileyCR (2009) Endocannabinoids and the heart. J Cardiovasc Pharmacol53: 267–276.
19.
HorderJBrowningMDi SimplicioM. (2012) Effects of 7 days treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing. J Psychopharmacol26: 125–132.
20.
JagerGRamseyNF (2008) Long-term consequences of adolescent cannabis exposure on the development of cognition, brain structure and function: an overview of animal and human research. Curr Drug Abuse Rev1: 114–123.
21.
Lopez-MorenoJAEcheverry-AlzateVBuhlerKM (2012) The genetic basis of the endocannabinoid system and drug addiction in humans. J Psychopharmacol26: 133–143.
22.
MachielsenMScheltema BeduinADekkerN. (2012) Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. J Psychopharmacol26: 189–195.
23.
MarcoEMLaviolaG (2012) The endocannabinoid system in the regulation of emotions throughout lifespan: a discussion on therapeutic perspectives. J Psychopharmacol26: 150–163.
24.
MarcoEMAdrianiWLlorenteR. (2009) Detrimental psychophysiological effects of early maternal deprivation in adolescent and adult rodents: altered responses to cannabinoid exposure. Neurosci Biobehav Rev33: 498–507.
25.
MinkkilaASaarioSNevalainenT (2010) Discovery and development of endocannabinoid-hydrolyzing enzyme inhibitors. Curr Top Med Chem10: 828–858.
26.
MoreiraFALutzB (2008) The endocannabinoid system: emotion, learning and addiction. Addict Biol13: 196–212.
27.
MoreiraFAAguiarDCResstelLB. (2012) Neuroanatomical substrates involved in cannabinoid modulation of defensive responses. J Psychopharmacol26: 40–55.
28.
OnaiviES (2009) Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications. Int Rev Neurobiol88: 335–369.
29.
OnaiviESIshiguroHGongJP. (2006) Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci1074: 514–536.
O’SullivanSEKendallDARandallMD (2009) Time-dependent vascular effects of endocannabinoids mediated by Peroxisome Proliferator-Activated Receptor Gamma (PPARgamma). PPAR Res2009: 425289.
32.
O’SullivanSEKendallPJKendallDA (2012) Endocannabinoids and the cardiovascular response to stress. J Psychopharmacol26: 71–82.
33.
PacherPMukhopadhyayPMohanrajR. (2008) Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations. Hypertension52: 601–607.
34.
PamplonaFATakahashiRN (2012) Psychopharmacology of the endocannabinoids: far beyond anandamide. J Psychopharmacol26: 7–22.
35.
PamplonaFABitencourtRMTakahashiRN (2008) Short- and long-term effects of cannabinoids on the extinction of contextual fear memory in rats. Neurobiol Learn Mem90: 290–293.
36.
PetrosinoSDi MarzoV (2010) FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs11: 51–62.
37.
RandallMDKendallDAO’SullivanS (2004) The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol142: 20–26.
RubinoTZamberlettiEParolaroD (2012) Adolescent exposure to cannabis as a risk factor for psychiatric disorders. J Psychopharmacol26: 177–188.
40.
RuehleSAparisi ReyARemmersF. (2012) The endocannabinoid system in anxiety, fear memory and habituation. J Psychopharmacol26: 23–39.
41.
SchachtJPSellingREHutchisonKE (2009) Intermediate cannabis dependence phenotypes and the FAAH C385A variant: an exploratory analysis. Psychopharmacology (Berl)203: 511–517.
42.
StokesPREgertonAWatsonB. (2012) History of cannabis use is not associated with alterations in striatal dopamine D2/D3 receptor availability. J Psychopharmacol26: 144–149.
43.
SuarezJBermudez-SilvaFJMackieK. (2008) Immunohistochemical description of the endogenous cannabinoid system in the rat cerebellum and functionally related nuclei. J Comp Neurol509: 400–421.
44.
Van SickleMDDuncanMKingsleyPJ. (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science310: 329–332.
45.
ViverosMPLlorenteRMorenoE. (2005a) Behavioural and neuroendocrine effects of cannabinoids in critical developmental periods. Behav Pharmacol16: 353–362.
46.
ViverosMPMarcoEMFileSE (2005b) Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav81: 331–342.
47.
ViverosMPLlorenteRSuarezJ. (2012) The endocannabinoid system in critical neurodevelopmental periods: sex differences and neuropsychiatric implications. J Psychopharmacol26: 164–176.
48.
WangMHillMNZhangL. (2012) Acute restraint stress enhances hippocampal endocannabinoid function via glucocorticoid receptor activation. J Psychopharmacol. 26: 56–70.
